PAGE
|
|
FINANCIAL STATEMENTS
|
|
F-2
|
|
F-3
|
|
F-4
|
|
F-5
|
|
F-6
|
IperionX Limited
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS For the six months ended December 31, 2023 and 2022 |
Condensed Consolidated Statement of Profit or Loss
and Other Comprehensive Income
FOR THE PERIODS ENDED DECEMBER 31, 2023 AND 2022
|
Six
Months Ended |
Six
Months Ended |
|||||||||
Note |
December 31, 2023
US$
|
December 31, 2022
US$
|
||||||||
Continuing operations
|
||||||||||
Research and development costs
|
(
|
)
|
(
|
)
|
||||||
Exploration and evaluation expenses
|
( |
) |
( |
) |
||||||
Corporate and administrative expenses
|
(
|
)
|
(
|
)
|
||||||
Business development expenses
|
(
|
)
|
(
|
)
|
||||||
Share-based payment expense
|
(
|
)
|
(
|
)
|
||||||
Finance income
|
|
|
||||||||
Finance costs
|
(
|
)
|
(
|
)
|
||||||
Other income and expenses
|
(
|
)
|
(
|
)
|
||||||
Loss before income tax
|
(
|
)
|
(
|
)
|
||||||
Income tax expense
|
|
|
||||||||
Loss for the period
|
(
|
)
|
(
|
)
|
||||||
Loss attributable to members of IperionX Limited
|
(
|
)
|
(
|
)
|
||||||
Other comprehensive income
|
||||||||||
Items that may be reclassified subsequently to profit or loss:
|
||||||||||
Exchange differences arising on translation of foreign operations
|
|
(
|
)
|
|||||||
Other comprehensive loss for the period, net of tax
|
|
(
|
)
|
|||||||
Total comprehensive loss for the period
|
(
|
)
|
(
|
)
|
||||||
Total comprehensive loss attributable to members of IperionX Limited
|
(
|
)
|
(
|
)
|
||||||
Loss per share
|
||||||||||
Basic and diluted loss per share (US$ per share)
|
(
|
)
|
(
|
)
|
IperionX Limited
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS For the six months ended December 31, 2023 and 2022 |
Note
|
December 31, 2023
US$
|
June 30, 2023
US$
|
||||||||||
ASSETS
|
||||||||||||
Current Assets
|
||||||||||||
Cash and cash equivalents
|
|
|
||||||||||
Trade and other receivables
|
|
|
||||||||||
Prepayments
|
|
|
||||||||||
Total Current Assets
|
|
|
||||||||||
Non-Current Assets
|
||||||||||||
Property, plant and equipment
|
4
|
|
|
|||||||||
Exploration and evaluation assets
|
5 |
|||||||||||
Prepayments |
||||||||||||
Total Non-Current Assets
|
|
|
||||||||||
TOTAL ASSETS
|
|
|
||||||||||
LIABILITIES
|
||||||||||||
Current Liabilities
|
||||||||||||
Trade and other payables
|
6
|
|
|
|||||||||
Loans and borrowings
|
7
|
|
|
|||||||||
Provisions
|
|
|
||||||||||
Total Current Liabilities
|
|
|
||||||||||
Non-Current Liabilities
|
||||||||||||
Loans and borrowings
|
7
|
|
|
|||||||||
Total Non-Current Liabilities
|
|
|
||||||||||
TOTAL LIABILITIES
|
|
|
||||||||||
NET ASSETS
|
|
|
||||||||||
EQUITY
|
||||||||||||
Contributed equity
|
8
|
|
|
|||||||||
Reserves
|
9
|
|
|
|||||||||
Accumulated losses
|
(
|
)
|
(
|
)
|
||||||||
TOTAL EQUITY
|
|
|
IperionX Limited
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS For the six months ended December 31, 2023 and 2022 |
Condensed Consolidated Statement of Changes in Equity
FOR THE PERIODS ENDED DECEMBER 31, 2023 AND 2022
|
Contributed
Equity
US$
|
Share-
Based
Payments
Reserve
US$
|
Foreign
Currency
Translation
Reserve
US$
|
Accumulated
Losses US$
|
Total
Equity
US$
|
||||||||||||||||
Balance at July 1, 2023
|
|
|
(
|
)
|
(
|
)
|
|
|||||||||||||
Net loss for the period
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||
Exchange differences arising on translation of foreign operations
|
|
|
|
|
|
|||||||||||||||
Total comprehensive loss
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||
Issue of shares - share placement
|
|
|
|
|
|
|||||||||||||||
Issue of shares - exercise of options
|
|
(
|
)
|
|
|
|
||||||||||||||
Issue of shares - conversion of RSUs
|
|
(
|
)
|
|
|
|
||||||||||||||
Issue of shares - conversion of employee rights
|
( |
) | ||||||||||||||||||
Issue of shares to a consultant |
( |
) | ||||||||||||||||||
Share issue costs
|
(
|
)
|
|
|
|
(
|
)
|
|||||||||||||
Share-based payment expense
|
|
|
|
|
|
|||||||||||||||
Balance at December 31, 2023
|
|
|
(
|
)
|
(
|
)
|
|
|||||||||||||
Balance at July 1, 2022
|
|
|
(
|
)
|
(
|
)
|
|
|||||||||||||
Net loss for the period
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||
Exchange differences arising on translation of foreign operations
|
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||
Total comprehensive loss
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||
Issue of shares - share placement
|
|
|
|
|
|
|||||||||||||||
Issue of shares - exercise of options
|
|
(
|
)
|
|
|
|
||||||||||||||
Issue of shares - conversion of RSUs
|
( |
) | ||||||||||||||||||
Share issue costs
|
(
|
)
|
|
|
|
(
|
)
|
|||||||||||||
Share-based payment expense
|
|
|
|
|
|
|||||||||||||||
Balance at December 31, 2022
|
|
|
(
|
)
|
(
|
)
|
|
IperionX Limited
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS For the six months ended December 31, 2023 and 2022 |
Note
|
Six Months Ended
December 31, 2023
US$
|
Six Months Ended
December 31, 2022
US$
|
||||||||||
Cash flows from operating activities
|
||||||||||||
Receipts from customers
|
||||||||||||
Payments to suppliers and employees
|
(
|
)
|
(
|
)
|
||||||||
Interest received
|
|
|
||||||||||
Interest paid
|
(
|
)
|
(
|
)
|
||||||||
Net cash flows used in operating activities
|
(
|
)
|
(
|
)
|
||||||||
Cash flows from investing activities
|
||||||||||||
Purchase of property, plant and equipment
|
( |
) | ( |
) | ||||||||
Purchase of exploration and evaluation assets
|
5
|
(
|
)
|
(
|
)
|
|||||||
Net cash flows used in investing activities
|
(
|
)
|
(
|
)
|
||||||||
Cash flows from financing activities
|
||||||||||||
Proceeds from issue of shares
|
|
|
||||||||||
Share issue costs
|
(
|
)
|
(
|
)
|
||||||||
Repayment of borrowings
|
(
|
)
|
(
|
)
|
||||||||
Payment of principal portion of lease liabilities
|
(
|
)
|
(
|
)
|
||||||||
Net cash flows from financing activities
|
|
|
||||||||||
Net increase in cash and cash equivalents
|
|
|
||||||||||
Net foreign exchange differences
|
(
|
)
|
|
|||||||||
Cash and cash equivalents at the beginning of the period
|
|
|
||||||||||
Cash and cash equivalents at the end of the period
|
|
|
IperionX Limited
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS For the six months ended December 31, 2023 and 2022 |
IperionX Limited
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS For the six months ended December 31, 2023 and 2022 |
Notes to the Condensed
Consolidated Financial Statements
FOR THE PERIODS ENDED DECEMBER 31, 2023 AND 2022 (continued)
|
|
Plant and
equipment
US$
|
Right-of-use
assets
US$
|
Total
US$
|
||||||||||
December 31, 2023
|
||||||||||||
Carrying value at July 1, 2023
|
|
|
|
|||||||||
Additions
|
|
|
|
|||||||||
Disposals |
( |
) | ( |
) | ||||||||
Depreciation
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Carrying amount at December 31, 2023
|
|
|
|
|||||||||
- at cost
|
|
|
|
|||||||||
- accumulated depreciation
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
June 30, 2023
|
||||||||||||
Carrying value at July 1, 2022
|
|
|
|
|||||||||
Additions
|
|
|
|
|||||||||
Depreciation
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Carrying amount at June 30, 2023
|
|
|
|
|||||||||
- at cost
|
|
|
|
|||||||||
- accumulated depreciation
|
(
|
)
|
(
|
)
|
(
|
)
|
IperionX Limited
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS For the six months ended December 31, 2023 and 2022 |
Notes to the Condensed
Consolidated Financial Statements
FOR THE PERIODS ENDED DECEMBER 31, 2023 AND 2022 (continued)
|
|
Titan Project
US$
|
||||
December 31, 2023
|
||||
Carrying value at July 1, 2023
|
|
|||
Additions
|
|
|||
Carrying amount at December 31, 2023 (1)
|
|
|||
June 30, 2023
|
||||
Carrying value at July 1, 2022
|
|
|||
Additions
|
|
|||
Carrying amount at June 30, 2023 (1)
|
|
(1)
|
|
December 31, 2023
US$
|
June 30, 2023
US$
|
|||||||
Current
|
||||||||
Trade payables
|
|
|
||||||
Accruals
|
|
|
||||||
Employee benefits
|
|
|
||||||
Total trade and other payables
|
|
|
IperionX Limited
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS For the six months ended December 31, 2023 and 2022 |
Notes to the Condensed
Consolidated Financial Statements
FOR THE PERIODS ENDED DECEMBER 31, 2023 AND 2022 (continued)
|
|
December 31, 2023
US$
|
June 30, 2023
US$
|
|||||||
Current
|
||||||||
Lease liabilities
|
|
|
||||||
Other loans and borrowings
|
|
|
||||||
Total current loans and borrowings
|
|
|
||||||
Non-current
|
||||||||
Lease liabilities
|
|
|
||||||
Other loans and borrowings
|
|
|
||||||
Total non-current loans and borrowings
|
|
|
||||||
Total loans and borrowings
|
|
|
December 31, 2023
US$
|
June 30, 2023
US$
|
|||||||
|
|
|
||||||
|
|
No. of
Ordinary
Shares
|
No. of Class A
Performance
Shares
|
No. of Class B
Performance
Shares
|
US$
|
|||||||||||||
December 31, 2023 |
||||||||||||||||
Opening balance at July 1, 2023
|
|
|
|
|
||||||||||||
Issue of shares - share placement
|
|
|
|
|
||||||||||||
Issue of shares - exercise of options
|
|
|
|
|
||||||||||||
Issue of shares - conversion of rights |
||||||||||||||||
Issue of shares - conversion of RSUs |
||||||||||||||||
Issue of shares to a consultant
|
|
|
|
|
||||||||||||
Share issue costs
|
-
|
-
|
-
|
(
|
)
|
|||||||||||
Closing balance at December 31, 2023
|
|
|
|
|
||||||||||||
December 31, 2022 |
||||||||||||||||
Opening balance at July 1, 2022
|
|
|
|
|
||||||||||||
Issue of shares - share placement
|
|
|
|
|
||||||||||||
Issue of shares - exercise of options
|
|
|
|
|
||||||||||||
Conversion of RSUs |
||||||||||||||||
Share issue costs
|
-
|
-
|
-
|
(
|
)
|
|||||||||||
Closing balance at December 31, 2022
|
|
|
|
|
IperionX Limited
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS For the six months ended December 31, 2023 and 2022 |
Notes to the Condensed
Consolidated Financial Statements
FOR THE PERIODS ENDED DECEMBER 31, 2023 AND 2022 (continued)
|
|
December 31, 2023
US$
|
June 30, 2023
US$
|
|||||||
Share based payments reserve
|
|
|
||||||
Foreign currency translation reserve
|
(
|
)
|
(
|
)
|
||||
Total reserves
|
|
|
No. of
Unlisted
Options
|
No. of
Performance
Rights
|
No. of
RSUs
|
US$
|
|||||||||||||
December 31, 2023
|
||||||||||||||||
Opening balance at July 1, 2023
|
|
|
|
|
||||||||||||
Grant of employee incentive securities
|
-
|
|
|
|
||||||||||||
Exercise of options
|
(
|
)
|
-
|
-
|
(
|
)
|
||||||||||
Conversion of RSUs
|
-
|
|
(
|
)
|
(
|
)
|
||||||||||
Conversion of performance rights |
- | ( |
) | ( |
) | |||||||||||
Issue of shares to a consultant
|
-
|
-
|
( |
) | ||||||||||||
Share-based payments expense
|
-
|
-
|
-
|
|||||||||||||
Closing balance at December 31, 2023
|
|
|
|
|
||||||||||||
December 31, 2022
|
||||||||||||||||
Opening balance at July 1, 2022
|
|
|
|
|
||||||||||||
Grant of employee incentive securities
|
|
|
|
|
||||||||||||
Exercise of options
|
(
|
)
|
-
|
-
|
(
|
)
|
||||||||||
Conversion of RSUs |
- | ( |
) | ( |
) | |||||||||||
Grant of options to advisor |
- | - | ||||||||||||||
Share-based payment expense
|
-
|
-
|
-
|
|
||||||||||||
Closing balance at December 31, 2022
|
|
|
|
|
Equity Interest |
|||||||||
Country of
Incorporation
|
December 31, 2023
%
|
June 30, 2023
%
|
|||||||
IperionX Inc.
|
|
|
%
|
|
%
|
||||
IperionX Critical Minerals, LLC
|
|
|
%
|
|
%
|
||||
IperionX Technology, LLC
|
|
|
%
|
|
%
|
||||
Hyperion Metals (Australia) Pty Ltd
|
|
|
%
|
|
%
|
||||
Calatos Pty Ltd, LLC
|
|
|
%
|
|
%
|
IperionX Limited
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS For the six months ended December 31, 2023 and 2022 |
Notes to the Condensed
Consolidated Financial Statements
FOR THE PERIODS ENDED DECEMBER 31, 2023 AND 2022 (continued)
|
|